These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 16497492)

  • 21. Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
    Sun J; Xu Y; Song S; Wu Z; Duan H
    Pharm Biol; 2011 Nov; 49(11):1167-72. PubMed ID: 22014264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model.
    Dalezis P; Geromichalos GD; Trafalis DT; Pissimissis N; Panagiotopoulou D; Galaktidou G; Papageorgiou E; Papageorgiou A; Daifoti Z; Lymperi M; Koutsilieris M
    In Vivo; 2012; 26(1):75-86. PubMed ID: 22210719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
    Helley D; Banu E; Bouziane A; Banu A; Scotte F; Fischer AM; Oudard S
    Eur Urol; 2009 Sep; 56(3):479-84. PubMed ID: 18585841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F; Duivenvoorden WC; Singh G
    Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A flexible unified approach to the analysis of pre-clinical combination studies.
    Harbron C
    Stat Med; 2010 Jul; 29(16):1746-56. PubMed ID: 20572122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro.
    Chou TC
    Contrib Gynecol Obstet; 1994; 19():91-107. PubMed ID: 7995057
    [No Abstract]   [Full Text] [Related]  

  • 28. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line.
    Geldof AA; Kruit A; Newling DW; Slotman BJ
    Anticancer Res; 1999; 19(1A):505-8. PubMed ID: 10226589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
    Jonker DM; Voskuyl RA; Danhof M
    Epilepsia; 2007 Mar; 48(3):412-34. PubMed ID: 17346245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships.
    El Naqa I; Suneja G; Lindsay PE; Hope AJ; Alaly JR; Vicic M; Bradley JD; Apte A; Deasy JO
    Phys Med Biol; 2006 Nov; 51(22):5719-35. PubMed ID: 17068361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
    Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. drexplorer: A tool to explore dose-response relationships and drug-drug interactions.
    Tong P; Coombes KR; Johnson FM; Byers LA; Diao L; Liu DD; Lee JJ; Heymach JV; Wang J
    Bioinformatics; 2015 May; 31(10):1692-4. PubMed ID: 25600946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relating isobolograms to response surfaces.
    Carter WH
    Toxicology; 1995 Dec; 105(2-3):181-8. PubMed ID: 8571355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of methods for evaluating drug-drug interaction.
    Zhao L; Au JL; Wientjes MG
    Front Biosci (Elite Ed); 2010 Jan; 2(1):241-9. PubMed ID: 20036874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.